How to Cite
Abstract
This study aimed to analyze changes in the plasma concentration of EGFR-mutated DNA occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). The study included 30 patients with EGFR mutation-driven non-small cell lung cancer (NSCLC). Serial plasma samples were collected before intake of the first tablet and at 0.5, 1, 2, 3, 6, 12, 24, 36 and 48 hours after the start of the therapy. EGFR-mutated plasma DNA (EGFR+ ctDNA) was detectable at diagnosis in 25 out of 30 study participants. There were different patterns of changes of the amount of circulating tumor DNA, i.e., the consistent decline of ctDNA content, or continuing increase of the number of circulating EGFR mutant copies, or alternating spikes and drops in the ctDNA concentration. Correlation with the disease outcome was observed only for the measurement performed at 48 hours. Twelve (50%) out of 24 informative patients showed >25% reduction of the ctDNA content at 48 h time point; all these patients demonstrated disease control after 4 and 8-12 weeks of therapy. The remaining 12 individuals showed either stable content of circulating EGFR+ DNA (n = 5) or the elevation of ctDNA concentration (n = 7). 10 of 12 patients with elevated or stable ctDNA level achieved an objective response at 4 weeks, but only 5 of 10 evaluable patients still demonstrated disease control at 8-12 weeks (p = 0.014, when compared to the group with ctDNA decrease). The decline of the amount of circulating EGFR mutant copies also correlated with longer progression-free survival (PFS; 14.7 months vs. 8.5 months, p = 0.013). Conclusion: Monitoring of plasma EGFR-M+ concentration within the first hours of the TKI therapy may be used as an immediate predictor of tumor response to the treatment.
References
Abbosh C, Birkbak NJ, Wilson GA. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution // Nature. 2017;545(7655):446–451.
Akhoundova D, Mosquera Martinez J, Musmann LE et al. The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer // Journal of clinical medicine. 2020;9(11):3674.
Anagnostou V, Forde PM, White JR et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer // Cancer research. 2019;79(6):1214–1225.
Ayeni D, Miller B, Kuhlmann A et al. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors // Journal for immunotherapy of cancer. 2019;7(1):1–15.
Bettegowda C, Sausen M, Leary R et al. Detection of circulating tumor DNA in early-and late-stage human malignancies // Science translational medicine. 2014;6(224):224ra24–224ra24.
Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P et al. Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: Results of a retrospective study // Cancer. 2020;126(15):3438–3447.
Charo LM, Eskander RN, Okamura R et al. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients // Molecular Oncology. 2021;15(1):67–79.
Conci N, Dall’Olio FG, Comellini V et al. «Lazarus effect» in patient affected by lung adenocarcinoma carrying EGFR, CTNNB1, MET exon 11 and PIK3CA mutations treated with gefitinib // Precision Cancer Medicine. 2020;3(23):1–5.
Ebert EBF, McCulloch T, Hansen KH et al. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer // Lung Cancer. 2020;141:37–43.
Fukuhara T, Saito H, Furuya N et al. Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study // EBioMedicine. 2020;57:102861.
Fung C, Chen X, Grandis JR, Duvvuri U. EGFR tyrosine kinase inhibition induces autophagy in cancer cells // Cancer biology & therapy. 2012;13(14):1417–1424.
Gobbini E, Swalduz A, Levra MG et al. Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer // Cancers. 2020;12(11):3112.
Yu HA, Schoenfeld AJ, Makhnin A et al. Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial // JAMA oncology. 2020;6(7):1048–1054.
Jia Y, Li X, Jiang T et al. EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies // International journal of cancer. 2019;145(5):1432-1444.
Jiang M, Gu DN, Dai JJ et al. Dark side of cytotoxic therapy: Chemoradiation-induced cell death and tumor repopulation // Trends in cancer. 2020;6(5):419–431.
Kim JO, Shin JY, Kim SR et al. Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer // Cancers. 2020;12(4):785.
Langer CJ. The «lazarus response» in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation // J Clin Oncol. 2009;27(9):1350–1354.
Moiseyenko VM, Procenko SA, Levchenko EV et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma // Oncology Research and Treatment. 2010;33(5):231–238.
Molina-Vila MA, Stahel RA, Dafni U et al. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial // Journal of Thoracic Oncology. 2020;15(3):416–425.
Nakamura Y, Sano K, Soda H et al. Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer // Journal of Thoracic Oncology. 2010;5(9):1404–1409.
Normanno N, Denis MG, Thress KS et al. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer // Oncotarget. 2017;8(7):12501.
Ono M, Hirata A, Kometani T et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation // Molecular cancer therapeutics. 2004;3(4):465–472.
Phallen J, Leal A, Woodward BD et al. Early noninvasive detection of response to targeted therapy in non–small cell lung cancer // Cancer research. 2019;79(6):1204–1213.
Reece M, Saluja H, Hollington P et al. The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer // Frontiers in genetics. 2019;10:1118.
Riediger AL, Dietz S, Schirmer U et al. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients // Scientific reports. 2016;6(1):1–8.
Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations // Journal of clinical oncology. 2013;31(27):3327–3334.
Serkova NJ, Eckhardt SG. Metabolic imaging to assess treatment response to cytotoxic and cytostatic agents // Frontiers in oncology. 2016;6:152.
Strijker M, Soer EC, de Pastena M et al. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma // International journal of cancer. 2020;146(5):1445–1456.
Venugopalan A, Lee M, Niu G et al. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models // Oncotarget. 2016;7(34):54137.
Wu K, Chang Q, Lu Y et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells // Oncotarget. 2013;4(12):2430.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021